Filing Flows › Immunocore Holdings (IMCR) › Capital expenditures
Immunocore Holdings (IMCR) capital expenditures by quarter
Immunocore Holdings' capital expenditures were $2.3M in Q3 2026 (third quarter 2026), +198% from Q2 2026. Over the last 4 quarters it ranged from $298K (Q1 2025) to $2.3M (Q3 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.3M | +198% | — |
| Q2 2026 | $786K | +90% | +90% |
| Q2 2025 | $414K | +39% | — |
| Q1 2025 | $298K | — | — |
Q3 2026 at a glance
Immunocore Holdings, Q3 2026: revenue $102M (-1% year over year), operating margin -13.3%, net loss $14.2M, operating cash flow $20.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Immunocore Holdings' capital expenditures?
Immunocore Holdings' capital expenditures were $2.3M in Q3 2026 (third quarter 2026), +198% from Q2 2026.
How has Immunocore Holdings' capital expenditures changed?
Over the last 4 quarters it ranged from $298K (Q1 2025) to $2.3M (Q3 2026).